Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM
Update on perioperative systemic therapy for urothelial carcinoma
Clin Adv Hematol Oncol (2019) 17:176-183.
Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint inhibitors are encouraging, but long-term follow-up is required. Randomized trials have failed to accrue a sufficient number of patients and have not demonstrated a survival benefit with adjuvant chemotherapy in MIUBC, but for those with high-risk features at surgery, adjuvant cisplatin-based therapy is appropriate. In upper tract urothelial carcinoma, several retrospective trials and one recent phase 2 prospective trial support the use of NAC, and a randomized trial with adjuvant chemotherapy demonstrated improved disease- and metastasis-free survival and a trend toward improved overall survival.
Publication Date: 2019-03-01.
Last updated on Wednesday, February 05, 2020